Dyne will also present encore data on zeleciment rostudirsen (z-rostudirsen, formerly known as DYNE-251, aninvestigational medicine being evaluated for the treatment of individuals with DMD mutations ...

ALTO-101 is an investigational phosphodiesterase-4 (PDE4) inhibitor delivered via a transdermal patch. Inhibition of the PDE4 enzyme is expected to enhance neural circuits and improve cognitive ...

DM1 cohort recruitment completion in Q4 2025, topline data in mid-2026, and potential BLA filing for z-basivarsen in late ...

The nurses who Ashton and Cliff Harris leaned on during the nearly three-and-a-half months their daughter was in the NICU ...

Explore the top 5 microwave ovens with advanced auto cook features available on Amazon, specifically focusing on models that ...

Investing.com -- Alto Neuroscience Inc (NYSE:ANRO) stock surged 32.3% Friday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug ...

The art of data strategy isn’t about dashboards or pipelines; it’s about mobilizing intelligence to create lasting value.

Scientists discovered a key molecular switch to keep neurons healthy by controlling the disassembly and assembly of their ...

Essendon captain Zach Merrett has given a cryptic speech addressing his future after winning a sixth club best and fairest ...

Two senior officials at the FDA's drug promotion regulatory office have resigned, leading to speculation that a clampdown on some direct-to-consumer (DTC) advertising of medicines could be on the way.